Fish Consumption Linked With Better Survival Outcomes in Colon Cancer

Video

This video examines the results of a prospective study that looked at associations between survival outcomes and fish and omega-3 fatty acid intake among colon cancer patients.

In this video, Erin Van Blarigan, ScD, of the University of California, San Francisco, discusses the results of a prospective study that looked at associations between survival outcomes and fish and long-chain omega-3 fatty acid intake after a colon cancer diagnosis.

The study included 1,011 stage III colon cancer patients who were part of an adjuvant chemotherapy trial, and found that patients who consumed dark meat fish at least twice per month had longer recurrence-free survival (hazard ratio [HR], 0.61; 0.44–0.83; P = .005), disease-free survival (HR, 0.64; 0.48–0.86; P = .007), and overall survival (HR, 0.68; 0.48–0.97; P = .05) compared with those who consumed no fish. The study also found that in patients with COX2 tumor expression, long-chain omega-3 fatty acid was associated with improved disease-free survival.

Results of the study (abstract 585) were presented last month at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content